ESTRO 2025 - Abstract Book

S3922

Radiobiology - Normal tissue radiobiology

ESTRO 2025

Results: 159(47.9%) patients developed sHT during a median follow-up of 3.86 years (range 0.29–8.54). The distribution of clinical and DVH data factors are listed in Table 1.a. The Logistic Regression model was chosen due to its best cross validation performance. The validation AUCs for TR and PR were 0.756 and 0.759, outperforming TD and PD. Including features from both glands improved AUC, notably for TR+PR(0.835) and TR+PD(0.845). The combined TR+TD+PR+PD model used 30 features to achieve an AUC of 0.85. It used 30 features comprising 12PR, 9TR, 5TD, and 4PD, with radiomics contributing most. The model combining all five feature groups reached the highest validation AUC of 0.855, where radiomics had the most predictive power.